PetVivo Holdings Inc (PETV) 2023 Q1 法說會逐字稿

Greetings, everyone, and welcome to the PetVivo Holdings' first-quarter of fiscal 2023 financial results conference call. I am John Dolan, the Chief Business Development Officer and General Counsel at PetVivo. Today's call is being webcast and will be posted on the company's website for playback.

Before we begin, I would like to remind everyone that comments made during this conference call by PetVivo executives may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties. Any statement that refers to expectations, projections, or other characterizations of future events, including financial projections or future market conditions is a forward-looking statement. PetVivo's actual future results could differ materially from those expressed in such forward-looking statements for any reason, including those listed in its SEC filings. PetVivo will assume no obligation to update any such forward-looking statements.

PetVivo filed its earnings release and Form 10-Q with the SEC today, which provides a detailed discussion of our financial results. These documents can be found in the SEC website and the investor relations section of our website.

I would like to turn the conference over to John Lai, the CEO and President of PetVivo. Please go ahead, John.

Thank you, John, and welcome. Joining me today is Robert Folkes, our Chief Financial Officer. I would like to begin discussing some highlights for the last quarter. Then Bob Folkes will discuss our financial results and financial condition in greater detail. I will continue by sharing some of the additional thoughts from our business strategy as well as key focus areas for fiscal 2023 before we open the line up for questions.

Our key highlights for the first quarter of fiscal 2023 were: we entered into a exclusive distribution and sales agreement with MWI, a subsidiary of Amerisource Bergen, ticker symbol ABC, which is a leading distributor of animal health products. We also have accounts now in 37 states. So that's a pretty we're getting good coverage in the mapped area. I would like to turn the call over to Robert Folkes, our Chief Financial Officer, to fully discuss recently completed register offering and our financial condition.

Well, thank you John, and good afternoon, everyone.

At June 30, 2022, the company had $4.4 million in cash and working capital of $3.8 million. We increased our inventory to $181,000 in order to support our expected revenue growth in 2023 -- fiscal '23. And as John mentioned, we've opened up our awareness -- the sales and marketing -- our investment in sales and marketing has been paying off with opening new accounts. And we continue to use the net proceeds from our initial public offering to expand our sales and marketing efforts and also clinical studies to gain vet acceptance and increase our revenues from the sale of Spryng.

And so now I will turn the call back to John.

Thank you, Bob. I would like to talk more about our business strategy and key focus areas for fiscal 2023. We talked about generating clinical evidence to support the equine and small animals market. And this is more of marketing studies and not a regulatory requirement. We're also going to be hiring additional sales territory managers to support our relationship with the MWI. And we're exhibiting at multiple conferences for both small animal and equine and creating awareness for Spryng. And we also have multiple influencers from the veterinary space that will be speaking at some of these major conventions.

Now, I would like to open it up for questions. Operator, can you please take over and explain the process?

(Operator Instructions) There is already someone with their hand raised. I'm going to allow them to talk. There you go. You should be able to talk now. It's the email gzcountry@gmail.

Hello, Gary. I believe that's you.

Operator, maybe we should go to another one and then come back to that one.

Okay. It looks like you're unmuted. So let us know if you can talk and then I don't see any other hands raised at this time.

We'll give him a few more seconds if there's no one else then.

And he's unmuted.

Yes, it looks like he's unmuted. So Riley, you want to repeat the process for people calling in just in case.

(Operator Instructions) We do have one more question who dialed in. The number ending in 3123, you can now talk.

Hello?

Yes.

John, can you hear me?

Yes, I can.

Great. Gary Zwetchkenbaum calling, and it is my understanding that there are several important clinical studies that are in progress. Can you give us an update on when these studies will be completed and when the data might be made available to us?

Yes. Pretty much all along, we have said these studies would be catalysts for speeding up adoption of the smaller animal vets as well as the equine vets.

I will turn this over to John Dolan, who is our General Counsel, Business Development person. He has been working with (technical difficulty) on the studies. John, can you take it over?

I can and actually, maybe the caller might want to mute their phone, right now. There we go.

No, and John is correct. Clinical studies and data is an incredibly large initiative for our company. We take that very seriously, and we have a number of them that have already been implemented or already are started and in progress as well as we are planning a number of them going forward in next 12 to 18 months. This will be an ongoing thing for us, and we plan to continue to do that, not only for our customers but also for our distributors.

Now, we've got two studies that are in progress right now that I can talk about. Of course, one is Colorado State University. This is a study where the principal investigator is very well-renowned veterinarian in the small animal space, his name is Felix Duerr. This study is basically set up to evaluate intra-articular injection of our product in the elbows of animals that have osteoarthritis.

We're anticipating that the study will be -- we're hoping that the study will be completed in Q4 of 2023. This is a long study because we want to basically test duration of the product also. So we anticipate that by Q4, the data should be accumulated. And we're anticipating sometime in Q1 of 2024 that those results will be released to the public.

We also have a study going on right now with a very well-known partner (technical difficulty) actually an institution that's owned by the National Veterinary Association, Ethos is the entity. And what that study is, the primary investigator is Chand Khanna, who is a well-known respected veterinarian in the United States for performing such studies. That study is to test intra-articular injections of Spryng in dogs with stifle disease.

And so we expect that study actually to have a completion date yet this year in Q3 of 2022. We anticipate, though it will -- that's the first phase of the study. The second phase we anticipate will be done before the end of the year, so that we'll have data as well as reports on this. And hopefully publication by sometime in Q1 of next year.

And those are calendar dates, not our fiscal dates.

Correct? That is correct, John.

Any other questions, operator?

No other hand raised at this time.

Okay. Then I would conclude the call. Thank you, operator, and thanks, everyone, for interest in PetVivo. We will remain focused on getting Spryng into the market as we can help dogs, horses with osteoarthritis. We also continue to work to develop other great products included in our OA product for felines.

Again, thank you for joining us on this call today. Thank you.